Company & Sponsor Intelligence
Johnson & Johnson Taiwan Ltd
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting0
Completed5
Countries0
Therapeutic footprint
adhdepilepsyschizophrenia
Indexed studies
NCT00518232A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
adhd · PHASE4
adhd · PHASE4
NCT01627860First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients
epilepsy · PHASE4
epilepsy · PHASE4
NCT00757705An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
schizophrenia · PHASE4
schizophrenia · PHASE4
NCT00758160The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
adhd · PHASE4
adhd · PHASE4
NCT00460720Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)
adhd · COMPLETED
adhd · COMPLETED
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →